AC Immune SA and Takeda collaboration on ACI 24.060 for the treatment of Azheimer's disease
Takeda and AC Immune SA announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI 24.060 for the treatment of Alzheimer’s disease. ACI 24.060 is an anti-Abeta active immunotherapy candidate designed to induce a robust antibody response against the toxic forms of Abeta believed to drive plaque formation and Alzheimer’s disease progression
By inducing plaque clearance and efficiently inhibiting potential to delay or slow Alzheimer’s disease progression. AC! 24.060 is being investigated in the ongoing ABATE randomized, double-blind, placebo-controlled Phase 1b/II trial to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of the investigational immunotherapy in subjects with prodromal Alzheimer’s disease and in adults with Down's syndrome.
1 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
